Literature DB >> 32016028

Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer.

Jarred P Reed1, Suzanne Devkota1, Robert A Figlin1.   

Abstract

Entities:  

Year:  2019        PMID: 32016028      PMCID: PMC6976491          DOI: 10.21037/atm.2019.10.27

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  15 in total

1.  The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Authors:  Vyara Matson; Jessica Fessler; Riyue Bao; Tara Chongsuwat; Yuanyuan Zha; Maria-Luisa Alegre; Jason J Luke; Thomas F Gajewski
Journal:  Science       Date:  2018-01-05       Impact factor: 47.728

2.  The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.

Authors:  Lisa Derosa; Bertrand Routy; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2018-04-18       Impact factor: 8.110

3.  Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials.

Authors:  S Sen; R Carmagnani Pestana; K Hess; G M Viola; V Subbiah
Journal:  Ann Oncol       Date:  2018-12-01       Impact factor: 32.976

4.  Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer.

Authors:  Taiki Hakozaki; Yusuke Okuma; Miwako Omori; Yukio Hosomi
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

5.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

6.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.

Authors:  Erick Riquelme; Yu Zhang; Liangliang Zhang; Maria Montiel; Michelle Zoltan; Wenli Dong; Pompeyo Quesada; Ismet Sahin; Vidhi Chandra; Anthony San Lucas; Paul Scheet; Hanwen Xu; Samir M Hanash; Lei Feng; Jared K Burks; Kim-Anh Do; Christine B Peterson; Deborah Nejman; Ching-Wei D Tzeng; Michael P Kim; Cynthia L Sears; Nadim Ajami; Joseph Petrosino; Laura D Wood; Anirban Maitra; Ravid Straussman; Matthew Katz; James Robert White; Robert Jenq; Jennifer Wargo; Florencia McAllister
Journal:  Cell       Date:  2019-08-08       Impact factor: 41.582

7.  Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.

Authors:  David J Pinato; Sarah Howlett; Diego Ottaviani; Heather Urus; Aisha Patel; Takashi Mineo; Cathryn Brock; Danielle Power; Olivia Hatcher; Alison Falconer; Manasi Ingle; Anna Brown; Dorothy Gujral; Sarah Partridge; Naveed Sarwar; Michael Gonzalez; Maggie Bendle; Conrad Lewanski; Thomas Newsom-Davis; Elias Allara; Mark Bower
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

8.  Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Authors:  Coureche Kaderbhai; Corentin Richard; Jean David Fumet; Anne Aarnink; Pascal Foucher; Bruno Coudert; Laure Favier; Aurélie Lagrange; Emeric Limagne; Romain Boidot; Francois Ghiringhelli
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

9.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Authors:  Ayelet Sivan; Leticia Corrales; Nathaniel Hubert; Jason B Williams; Keston Aquino-Michaels; Zachary M Earley; Franco W Benyamin; Yuk Man Lei; Bana Jabri; Maria-Luisa Alegre; Eugene B Chang; Thomas F Gajewski
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

10.  Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.

Authors:  Florian Huemer; Gabriel Rinnerthaler; Theresa Westphal; Hubert Hackl; Georg Hutarew; Simon Peter Gampenrieder; Lukas Weiss; Richard Greil
Journal:  Oncotarget       Date:  2018-03-27
View more
  5 in total

1.  Identification of key genes in cutaneous squamous cell carcinoma: a transcriptome sequencing and bioinformatics profiling study.

Authors:  Dan-Dan Zou; Dan Xu; Yuan-Yuan Deng; Wen-Juan Wu; Juan Zhang; Ling Huang; Li He
Journal:  Ann Transl Med       Date:  2021-10

Review 2.  The Oncobiome in Gastroenteric and Genitourinary Cancers.

Authors:  Domenica Lucia D'Antonio; Simona Marchetti; Pamela Pignatelli; Adriano Piattelli; Maria Cristina Curia
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

Review 3.  Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors.

Authors:  Ondřej Kubeček; Pavla Paterová; Martina Novosadová
Journal:  Life (Basel)       Date:  2021-12-11

Review 4.  Diet, Microbiome, and Cancer Immunotherapy-A Comprehensive Review.

Authors:  Michał Szczyrek; Paulina Bitkowska; Patryk Chunowski; Paulina Czuchryta; Paweł Krawczyk; Janusz Milanowski
Journal:  Nutrients       Date:  2021-06-28       Impact factor: 5.717

Review 5.  A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.

Authors:  Jie Zhang; Zhujiang Dai; Cheng Yan; Wenjie Zhang; Daorong Wang; Dong Tang
Journal:  Clin Transl Oncol       Date:  2021-06-14       Impact factor: 3.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.